Who Optimizes SG&A Costs Better? Bristol-Myers Squibb Company or argenx SE

SG&A Cost Management: BMY vs. argenx SE

__timestamp	Bristol-Myers Squibb Company	argenx SE
Wednesday, January 1, 2014	5699000000	4241601.57
Thursday, January 1, 2015	5001000000	5392385.38
Friday, January 1, 2016	5002000000	7370036.73
Sunday, January 1, 2017	4849000000	14970357
Monday, January 1, 2018	4551000000	31413266
Tuesday, January 1, 2019	4871000000	72279461
Wednesday, January 1, 2020	7661000000	183907682
Friday, January 1, 2021	7690000000	307644000
Saturday, January 1, 2022	7814000000	472132000
Sunday, January 1, 2023	7772000000	709539000
Monday, January 1, 2024	8414000000

Unveiling the hidden dimensions of data

Optimizing SG&A Costs: A Tale of Two Companies

In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Bristol-Myers Squibb Company (BMY) and argenx SE (ARGX) offer a fascinating study in contrasts over the past decade. From 2014 to 2023, BMY's SG&A expenses have consistently been higher, peaking at approximately $7.8 billion in 2022. In contrast, argenx SE, a smaller player, has seen its SG&A costs rise from a modest $4.2 million in 2014 to $709 million in 2023, reflecting its rapid growth.

While BMY's expenses have grown by about 36% over this period, argenx SE's have skyrocketed by over 16,600%, highlighting its aggressive expansion strategy. This data underscores the different stages and strategies of these companies, with BMY focusing on maintaining its market position and argenx SE on scaling up its operations.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025